Andrea Rigamonti, Italy
Ospedale San Raffaele UO Pediatric, Diabetes Research Institute,Presenter of 1 Presentation
MEDTRONIC 640G VS TANDEM BASAL IQ DURING THE FIRST 3 MONTHS OF DIABETES SINCE ONSET IN VERY YOUNG CHILDREN.
Abstract
Background and Aims
Type 1 diabetes (T1D) management in young children is challenging due to the risk of wide glucose fluctuations and their long-term consequences. The aim of this study was to compare the use of Medtronic 640G and off-label use of Tandem Basal IQ in children with T1D younger than 6 years of age.
Methods
Twentyone children (mean age 3 years) were started on either 640G (n=11) or Tandem Basal IQ (n=10) at onset and pump/sensor data was downloaded after 3 months. Parents of children started on Tandem signed an informed consent. Mann-Whitney non-parametric U test was used to assess differences in glucometrics between group.
Results
Glucometric parameters of 640G vs Tandem useres were respectively: TIR 75% vs 63%, TBR 2.4% vs 3%, TAR 21.6% vs 34%, CV 32 vs 38. Mean insulin dose was 0.4U/kg/die in the 640G group and 0.7U/kg/die in the Tandem group. Differences in glucose distributions were all statistically significant except for TBR. No episoides of severe hypoglycemia or DKA were reported.
Conclusions
Both pumps allowed these young children to obtain good glucose control. However, Medtronic 640G achieved significantly better glucose distributions, although this may be partially explained by the lower daily insulin needs in this group. Our data suggests that the use of Tandem Basal IQ in children <6 years is safe, feasible and may be a valid alternative to other systems in young children in whom also few capillary glucose calibrations may be challenging. Broader prospective studies in this delicate population are required to confirm our results.